Dehghani et al. analyzed HER2-low and HER2-zero patients in triple-negative BC and found that HER2-low tumors had lower lymph node involvement rates, less lymphatic invasion, and lower local recurrence rates [42]. The gene discussed is ERBB2; the disease is breast cancer.